Professor Ken Ho
Senior Principal Research Fellow; Director, Pituitary Research Unit, Garvan Institute of Medical Research; Professor of Medicine, The University of New South Wales; Chairman, Dept of Endocrinology, St Vincent's Hospital, Sydney; Visiting Physician, St Vincent's Private Hospital, Sydney
Email: k.ho 'at' garvan.org.au
Research Group: Pituitary, Hormones & Metabolism
Ken's other professional appointments include: Professor of Medicine, University of New South Wales; Chairman, Dept of Endocrinology, St Vincent's Hospital Sydney; and Visiting Physician, St Vincent's Private Hospital Sydney.
Ken obtained his medical degree at the University of Sydney and doctorate degree from the University of New South Wales and undertook postdoctoral studies at the University of Virginia. He is a past-president of the Endocrine Society of Australia and president of the Growth Hormone Research Society. He has published over 150 scientific papers, which include publications in the Lancet, Annals of Internal Medicine, Journal of Clinical Investigations and PNAS.
Education
1985 MD, The University of New South Wales
1983 VQE
1981 FRACP
1975 ECFMG
1975 MB., BS (Hons), University of Sydney
1967 LMus A (pianoforte), NSW Conservatorium of Music
Awards and Honours
2008 Asia Oceania Medalist of the British Endocrine Society
2000 Clinical Endocrinology Trust Medal
1995 Merck Award, The Endocrine Society (Dr. AJ O'Sullivan, PhD student)
1984-86 Postgraduate Medical Scholarship, University of Sydney Foundation
1984 Blackburn Fellowship, Royal Australasian College of Physician
Publications
Leung K-C, Johannsson G, Leong GM, Ho KKY. Estrogen regulation of growth hormone action. Endocrine Reviews 2004; 25(5):693-721.
Leung KC, Ballesteros M, Doyle N, Watts CKW, Low TH, Ross RJM, Leong GM, Ho KKY. Estrogen inhibits growth hormone (GH) signaling by supressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS2. Proc Natl Acad Sci 2003; 100:1016-1021
Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KKY. Physiological and pharmacological regulation of 20-kDa GH. Am J Physiol Endocrinol Metab 2002; 283:E836-E843
Hartman ML, Crowe BJ, Biller BMK, Ho KKY, Clemmons DR, Chapman JJ. Which patients do not require a growth hormone stimulation test for the diagnosis of adult growth hormone deficiency? J Clin Endocr Metab 2001; 87:477-485
Ho KKY. The role of pegvisamont in acromegaly. Lancet (Invited Editorial). 2001; 358: 1743-1744
Wolthers T, Hoffman D, Nugent AG, Duncan M, Sonkson P, Ho KKY. Oral estrogen impairs the metabolic effects of growth hormone (GH) in GH deficient women. Am J Physiol 2001; 281:E1191-E1196
Ross RJM, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KKY. Binding and functional studies with the growth hormone receptor antagonist B2036-PEG (Pegvisomant). J Clin Endocr Metab 2001; 86:1716-1723
Leung KC, Waters, MJ, Markus I, Baumbach W, Ho KKY. Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: A novel mechanism of growth hormone receptor regulation. Proc Natl Acad Sci 1997; 94:11381-11386
O'Sullivan AJ, Crampton L, Freund J, Ho, KKY. The route of estrogen administration confers distinct effects on energy metabolism and body composition in postmenopausal women. J Clin Invest 1998; 102:1035-1040
Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KKY. Diagnosis of growth hormone deficiency in adults. Lancet 1994; 343:1064-1068
